Vuong Trieu

Dr. Trieu, an expert in pharmaceutical development, currently serves as CEO/Chairman of Oncotelic Inc. Dr. Trieu deep domain expertise on RNA therapeutics starting with being Group Leader at Genetic Therapy Inc. to CEO/Executive Chairman of Marina Biotech a company developing RNA therapeutics- especially tkRNAi. He was also President and CEO of Igdrasol- developer of 2nd generation Abraxane- where he pioneered the regulatory pathway for approval of paclitaxel nanomedicine through a single bioequivalence trial against Abraxane. When Igdrasol merged with Sorrento Therapeutics, he became CSO and Board Director. He was Board Director of Cenomed- a company focusing on CNS drug development. Before that he was Director of Pharmacology, Pharmacokinetics, and Biology at Abraxis where he leads the development of albumin encapsulated therapeutics along building high throughput platform for small molecules, miRNA, kinases. Prior to that, he was Group Leader at Applied Molecular Evolution where he was developing a bit better for Humira and Enbrel. Before that, he was Director of Cardiovascular Biology at Parker Hughes Institute. Dr. Trieu holds a Ph.D. in Microbiology, BS in Microbiology and Botany. He is a member of ENDO, ASCO, AACR, and many other professional organizations. Dr. Trieu published widely in oncology, cardiovascular, and drug development. Dr. Trieu has over 100 patent applications and 39 issued US patents.

Speaker Details